Adhera Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223018516 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.00K $69.00K $40.00K
YoY Change -93.17% 72.5% 3900.0%
Cash & Equivalents $58.00K $69.00K $40.00K
Short-Term Investments
Other Short-Term Assets $24.00K $35.00K $130.0K
YoY Change -81.1% -73.08%
Inventory
Prepaid Expenses $24.00K $35.00K
Receivables
Other Receivables
Total Short-Term Assets $82.00K $104.0K $170.0K
YoY Change -91.6% -38.82% 16900.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $82.00K $104.0K $170.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $82.00K $104.0K $170.0K
YoY Change -91.6% -38.82% 16900.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.318M $2.410M $2.287M
YoY Change -0.9% 5.38% 1.42%
Accrued Expenses $5.139M $4.725M $3.467M
YoY Change 39.0% 36.28% 44.82%
Deferred Revenue
YoY Change
Short-Term Debt $1.176M $1.228M $1.151M
YoY Change 13.19% 6.69% -82.0%
Long-Term Debt Due $9.415M $8.398M $5.677M
YoY Change 49.28% 47.93%
Total Short-Term Liabilities $22.87M $23.20M $25.67M
YoY Change 9.05% -9.63% 65.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $22.87M $23.20M $25.67M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $22.87M $23.20M $25.67M
YoY Change 9.05% -9.63% 65.54%
SHAREHOLDERS EQUITY
Retained Earnings -$56.40M -$56.70M
YoY Change 5.22%
Common Stock $23.00K $19.00K
YoY Change -93.93%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.000K $2.000K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$22.80M -$23.10M -$25.50M
YoY Change
Total Liabilities & Shareholders Equity $82.00K $104.0K $170.0K
YoY Change -91.6% -38.82% 16900.0%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000737207
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q1 us-gaap Loan Processing Fee
LoanProcessingFee
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Loan Processing Fee
LoanProcessingFee
usd
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
usd
CY2023Q1 ATRX Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-13789
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ADHERA THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2658569
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
8000 Innovation Parkway
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70820
CY2023Q1 dei City Area Code
CityAreaCode
(919)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
518-3748
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3489454 shares
CY2023Q1 us-gaap Cash
Cash
69000 usd
CY2022Q4 us-gaap Cash
Cash
32000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
104000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
79000 usd
CY2023Q1 us-gaap Assets
Assets
104000 usd
CY2022Q4 us-gaap Assets
Assets
79000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2410000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2397000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4725000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4373000 usd
CY2023Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
525000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
498000 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
8398000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7333000 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1228000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1252000 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5890000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6386000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23197000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22265000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
23197000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22265000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3178738 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3178738 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3160877 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3160877 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33553000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33548000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56663000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55751000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5594 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5594 shares
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23093000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22186000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
353000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
260000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
353000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
260000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-353000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-260000 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
334000 usd
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
311000 usd
CY2023Q1 ATRX Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
717000 usd
CY2022Q1 ATRX Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
667000 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
39000 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
5000 usd
CY2023Q1 us-gaap Loan Processing Fee
LoanProcessingFee
347000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
608000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
175000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-533000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
186000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-533000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74000 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26000 usd
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
364000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-912000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-438000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3176952 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
858959 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-25106000 usd
CY2022Q1 us-gaap Dividends
Dividends
364000 usd
CY2022Q1 ATRX Stock Issued During Period Value Conversion With Convertible Note
StockIssuedDuringPeriodValueConversionWithConvertibleNote
18000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
28000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25498000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22186000 usd
CY2023Q1 us-gaap Dividends
Dividends
26000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23093000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74000 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
608000 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
175000 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
334000 usd
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
311000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
717000 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
667000 usd
CY2023Q1 us-gaap Loan Processing Fee
LoanProcessingFee
347000 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
39000 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
5000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-12000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
23000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
46000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-310000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-216000 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
500000 usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
200000 usd
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
58000 usd
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
20000 usd
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
95000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
347000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
180000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
4000 usd
CY2023Q1 ATRX Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
265000 usd
CY2022Q1 ATRX Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
18000 usd
CY2022Q1 us-gaap Stock Issued1
StockIssued1
28000 usd
CY2023Q1 ATRX Accrued And Deemed Dividends
AccruedAndDeemedDividends
26000 usd
CY2022Q1 ATRX Accrued And Deemed Dividends
AccruedAndDeemedDividends
364000 usd
CY2023Q1 us-gaap Cash
Cash
69000 usd
CY2023Q1 ATRX Working Capital
WorkingCapital
23100000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-310000 usd
CY2023Q1 ATRX Working Capital
WorkingCapital
23100000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23100000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56700000 usd
CY2023Q1 us-gaap Loans Payable
LoansPayable
8398000 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
7333000 usd
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20 reverse stock split
CY2023Q1 us-gaap Cash
Cash
69000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zi40NXp3sxJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zLqSNgzwKkY8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5890000 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
5890000 usd
CY2022Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
6386000 usd
CY2023Q1 ATRX Initial Valuation Of Derivative Liabilities Included In Debt Discount
InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount
265000 usd
CY2023Q1 ATRX Initial Valuation Of Derivative Liabilities Included In Derivative Expense
InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense
422000 usd
CY2023Q1 ATRX Reclassification Of Derivative Liabilities To Gain On Debt Extinguishment
ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment
-44000 usd
CY2023Q1 ATRX Change In Fair Value Included In Derivative Expense Income
ChangeInFairValueIncludedInDerivativeExpenseIncome
-1139000 usd
CY2023Q1 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
5890000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74000 usd
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
26000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
364000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-912000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-438000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3176952 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
858959 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15226886 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9111903 shares
CY2023Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
35000 usd
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
47000 usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
9157000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
8042000 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
759000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
709000 usd
CY2022Q4 us-gaap Debt Instrument Description
DebtInstrumentDescription
(i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest
CY2022Q1 us-gaap Debt Instrument Description
DebtInstrumentDescription
the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1228000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1319000 usd
CY2022Q4 ATRX Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
67000 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1228000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1252000 usd
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
107728 usd
CY2022Q1 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.16 pure
CY2022Q3 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.18 pure
CY2021 ATRX Reclassification Of Additional Paid In Capital To Derivative Liability
ReclassificationOfAdditionalPaidInCapitalToDerivativeLiability
3462000 usd
CY2023Q1 ATRX Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2022Q4 ATRX Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6785914 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
238141 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1129098 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
1217337 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9370490 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1600000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.60
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.60
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
19000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.60
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
19000 shares
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P0Y1M2D
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
19.60
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
19000 shares
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
19.60
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd

Files In Submission

Name View Source Status
0001493152-23-018516-index-headers.html Edgar Link pending
0001493152-23-018516-index.html Edgar Link pending
0001493152-23-018516.txt Edgar Link pending
0001493152-23-018516-xbrl.zip Edgar Link pending
atrx-20230331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
atrx-20230331_cal.xml Edgar Link unprocessable
atrx-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atrx-20230331_lab.xml Edgar Link unprocessable
atrx-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending